Page 30 - 2019_04-Haematologica-web

V.R. Gordeuk et al.
42. Paffett-Lugassy N, Hsia N, Fraenkel PG, et
al. Functional conservation of erythropoietin signaling in zebrafish. Blood. 2007;110(7): 2718-2726.
43. Shibata J, Hasegawa J, Siemens HJ, et al. Hemostasis and coagulation at a hematocrit level of 0.85: functional consequences of erythrocytosis. Blood. 2003;101(11):4416- 4422.
44. Lamrani L, Lacout C, Ollivier V, et al. Hemostatic disorders in a JAK2V617F-dri- ven mouse model of myeloproliferative neo- plasm. Blood. 2014;124(7):1136-1145.
45. Strassel C, Kubovcakova L, Mangin PH, et al. Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. Thromb Haemost. 2015;113(2):414-425.
46. Walton BL, Lehmann M, Skorczewski T, et al. Elevated hematocrit enhances platelet accumulation following vascular injury. Blood. 2017;129(18):2537-2546.
47. Prchal JT. Secondary polycythemia erythro- cytosis. Chapter 57. In: Kaushansky K, Lichtman MA, Prchal JT, et al., eds. Williams Hematology 9th Edition. New York, NY: McGraw Hill; 2015:871-888.
48. Sergueeva A, Miasnikova G, Shah BN, et al. Prospective study of thrombosis and throm- bospondin-1 expression in Chuvash poly- cythemia. Haematologica. 2017;102(5): e166-e169.
49. Liu E, Percy MJ, Amos CI, et al. The world- wide distribution of the VHL 598C>T muta- tion indicates a single founding event. Blood. 2004;103(5):1937-1940.
50. Miasnikova GY, Sergueeva AI, Nouraie M, et al. The heterozygote advantage of the Chuvash polycythemia VHLR200W muta- tion may be protection against anemia. Haematologica. 2011;96(9):1371-1374.
51. Sergueeva AI, Miasnikova GY, Polyakova LA, Nouraie M, Prchal JT, Gordeuk VR. Complications in children and adolescents with Chuvash polycythemia. Blood. 2015;125(2):414-415.
52. McClain DA, Abuelgasim KA, Nouraie M, et al. Decreased serum glucose and glycosy- lated hemoglobin levels in patients with Chuvash polycythemia: a role for HIF in glu- cose metabolism. J Mol Med (Berl). 2013;91(1):59-67.
53. Yoon D, Okhotin DV, Kim B, et al. Increased size of solid organs in patients with Chuvash polycythemia and in mice with altered expression of HIF-1alpha and HIF- 2alpha. J Mol Med. 2010;88(5):523-530.
54. Stavik B, Espada S, Cui XY, et al. EPAS1/HIF- 2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro- thrombotic potential in endothelial cells. Biochim Biophys Acta. 2016;1862(4):670- 678.
55. Sun L, Liu Y, Lin S, et al. Early growth response gene-1 and hypoxia-inducible fac- tor-1alpha affect tumor metastasis via regu- lation of tissue factor. Acta Oncol. 2013;52(4):842-851.
56. Narita I, Shimada M, Yamabe H, et al. NF- kappaB-dependent increase in tissue factor expression is responsible for hypoxic podocyte injury. Clin Exp Nephrol. 2016;20(5):679-688.
57. Berk P, Wasserman L, Fruchtman S. Treatment of polycythemia vera. A summa- ry of clinical trials conducted by the Polycythemia Study Group. In: Wasserman L, Berk P, Berlin N, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia: WB Saunders; 1995.
58. Reeves BN, Song J, Kim SJ, et al. Upregulation of tissue factor may contribute to thrombosis in PV and ET. American Society of Hematology Annual Meeting. San Diego, CA; 2018.
59. Gordeuk VR, Chung DW, Shah BN, et al. Thrombosis and von Willebrand factor in Chuvash polycythemia. Blood. 2017;130 (Suppl 1):2377.
60. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-2232.
61. Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2012;2012:571-581.
62. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospec- tive analysis of 260 patients. Ann Hematol. 1991;63(2):101-106.
63. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-124.
64. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5(4):708-714.
The haematocrit and platelet target in poly- cythemia vera. Br J Haematol. 2007;136(2): 249-259.
73. Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. Am J Hematol. 2017;92(11):1131-1136.
74. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treat- ment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
75. Dingli D, Tefferi A. Hydroxyurea: the drug of choice for polycythemia vera and essen- tial thrombocythemia. Curr Hematol Malig Rep. 2006;1(2):69-74.
76. Barbui T, Finazzi G. Evidence-based man- agement of polycythemia vera. Best Pract Res Clin Haematol. 2006;19(3):483-493.
77. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34(1):17-23.
78. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk fac- tor in patients with polycythemia vera. Blood. 2007;109(6):2446-2452.
79. Barbui T, De Stefano V, Ghirardi A, Masciulli A, Finazzi G, Vannucchi AM. Different effect of hydroxyurea and phle- botomy on prevention of arterial and venous thrombosis in polycythemia vera. Blood Cancer J. 2018;8(12):124.
80. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96(13):4261-4266.
81. Vannucchi AM. Insights into the pathogene- sis and management of thrombosis in poly- cythemia vera and essential thrombo- cythemia. Intern Emerg Med. 2010;5(3):177-
65. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as
the clue to an underlying myeloproliferative
disorder in patients with Budd-Chiari syn-
drome or portal vein thrombosis. Semin 184.
Thromb Hemost. 1997;23(5):411-418.
66. Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost.
2007;5(1):55-61.
67. Reikvam H, Tiu RV. Venous thromboem-
bolism in patients with essential thrombo- cythemia and polycythemia vera. Leukemia. 2012;26(4):563-571.
68. Spivak JL. Polycythemia vera: myths, mech- anisms, and management. Blood. 2002;100(13):4272-4290.
69. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978;2(8102):1219-1222.
70. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in poly- cythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23(2):132-143.
71. Berlin NI, Wasserman LR. Polycythemia vera: a retrospective and reprise. J Lab Clin Med. 1997;130(4):365-373.
72. Di Nisio M, Barbui T, Di Gennaro L, et al.
82. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an inter- national study. Leukemia. 2013;27(9):1874- 1881.
83. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leuko- cytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost. 2006;4(12):2593-2598.
84. Zangari M, Fink L, Tolomelli G, et al. Could hypoxia increase the prevalence of thrombot- ic complications in polycythemia vera? Blood Coagul Fibrinolysis. 2013;24(3):311-316.
85. Ruiz-Arguelles GJ. Altitude above sea level as a variable for definition of anemia. Blood. 2006;108(6):2131; author reply 2131-2132.
86. Pilli VS, Datta A, Afreen S, Catalano D, Szabo G, Majumder R. Hypoxia downregu- lates protein S expression. Blood. 2018;132(4):452-455.
87. Bar-Natan M, Hoffman R. New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches. Haematologica. 2019;104(1):3-6.
658
haematologica | 2019; 104(4)